All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Mepolizumab granted approval by FDA for the treatment of hypereosinophilic syndrome

Oct 5, 2020

Mepolizumab, an anti-interlukin-5 (IL-5) monoclonal antibody, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of children ≥ 12 years of age and adult patients with hypereosinophilic syndrome (HES) for ≥ 6 months without another identifiable non-blood related cause of the disease. This is the first approval for patients with HES in almost 14 years, and was based on a phase III study evaluating the efficacy and safety of mepolizumab versus placebo in patients with HES, where mepolizumab demonstrated a significant reduction in the frequency of flares and blood eosinophil levels compared with placebo. Read more data from this study here.

HES represent a group of rare myeloproliferative neoplasms characterized by elevated eosinophil levels, which may lead to organ damage and can be life threatening if not treated. IL-5 is known to play a role in eosinophil growth, and mepolizumab has been approved for the treatment of diseases which are driven by eosinophils, such as asthma and eosinophilic granulomatosis.

Mepolizumab has been associated with herpes zoster infections and vaccination is advised if medically appropriate.

  1. FDA News Release. FDA approves first drug to treat group of rare blood disorders in nearly 14 years. Published Sep 25, 2020. Accessed Oct 05, 2020.